Metraipolis › archive › dc_f2b975bd508b

Standardization of in-house anti-IgG and IgA ELISAs for the detection of COVID-19 — Europe PMC PMID:37294808

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/37294808
DOI: 10.1371/journal.pone.0287107
License (as archived): CC0-1.0
Archived: 2026-10-07T12:59:33.389Z
SHA-256 of the archived text: d3c2af3106a823a3cda272a3aaa4722a813f6f770c61311f5d7f58b9b144ecd3
Stable URL of this page: https://metraipolis.com/documento/dc_f2b975bd508b

How to cite

Standardization of in-house anti-IgG and IgA ELISAs for the detection of COVID-19 — Europe PMC PMID:37294808 — Europe PMC (en), https://europepmc.org/article/MED/37294808 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_f2b975bd508b (Metraipolis archive dc_f2b975bd508b, sha256 d3c2af3106a823a3cda272a3aaa4722a813f6f770c61311f5d7f58b9b144ecd3)

BibTeX

@misc{dcf2b975bd508b,
  title = {Standardization of in-house anti-IgG and IgA ELISAs for the detection of COVID-19 — Europe PMC PMID:37294808},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/37294808},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_f2b975bd508b; sha256 d3c2af3106a823a3cda272a3aaa4722a813f6f770c61311f5d7f58b9b144ecd3},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/37294808. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19). RT-PCR detection of viral RNA represents the gold standard method for diagnosis of COVID-19. However, multiple diagnostic tests are needed for acute disease diagnosis and assessing immunity during the COVID-19 outbreak. Here, we developed in-house anti-RBD IgG and IgA enzyme-linked immunosorbent assays (ELISAs) using a well-defined serum sample panel for screening and identification of human SARS-CoV-2 infection. We found that our in-house anti-SARS-CoV-2 IgG ELISA displayed a 93.5% sensitivity and 98.8% specificity whereas our in-house anti-SARS-CoV-2 IgA ELISA provided assay sensitivity and specificity at 89.5% and 99.4%, respectively. The agreement kappa values of our in-house anti-SARS-CoV-2 IgG and IgA ELISA assays were deemed to be excellent and fair, respectively, when compared to RT-PCR and excellent for both assays when compared to Euroimmun anti-SARS-CoV-2 IgG and IgA ELISAs. These data indicate that our in-house anti-SARS-CoV-2 IgG and IgA ELISAs are compatible performing assays for the detection of SARS-CoV-2 infection.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2023 (prima pubblicazione 2023-06-09).
Identificativi: PMID 37294808 · PMCID PMC10256204 · DOI 10.1371/journal.pone.0287107.
Descrittori MeSH principali: COVID-19.
Pagina: https://europepmc.org/article/MED/37294808 — https://doi.org/10.1371/journal.pone.0287107. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-07T12:29:42.070Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.